Thomas Gelzleichter
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Air Quality and Health Impacts, Fibroblast Growth Factor Research, Immunotherapy and Immune Responses, Liver physiology and pathology
Most-Cited Works
- → Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies(2009)267 cited
- → GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer(2021)132 cited
- → Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex(2015)107 cited
- → Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans(2020)89 cited
- → A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys(2006)78 cited
- → A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes(2011)77 cited
- → Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer(2021)75 cited
- → Concentration-response relationships of rat lungs to exposure to oxidant air pollutants: A critical test of Haber's Law for ozone and nitrogen dioxide(1992)59 cited
- → Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates(2006)59 cited
- → Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates(2007)58 cited